- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: 2-[[(2R)-2-[[2-[(3,3-dibutyl-7-methylsulfanyl-1,1-dioxo-5-phenyl-2,4-dihydro-1λ6,5-benzothiazepin-8-yl)oxy]acetyl]amino]-2-phenylacetyl]amino]acetic acid | A3309 | AJG533 | AZD-7806 | AZD7806 | Goofice®
elobixibat is an approved drug (Japan (2018))
Compound class: Synthetic organic
Comment: Elobixibat is an orally available inhibitor of the ileal bile acid transporter (IBAT or ASBT), which is the protein product of the SLC10A2 gene. It is being evaluated for clinical utility in the management of chronic constipation [1,3,6]. The chemical structure is claimed as Example 14 in Albireo Ab's patent US20130225511A1  (we have chosen this iteration of the patent as it has both chemical structure images and data included in online versions).
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
1. Acosta A, Camilleri M. (2014)
Elobixibat and its potential role in chronic idiopathic constipation.
Therap Adv Gastroenterol, 7 (4): 167-75. [PMID:25057297]
2. Gillberg P-G, Graffner H, Starke I. (2013)
Ibat inhibitors for the treatment of liver diseases.
Patent number: US20130225511A1. Assignee: Albireo AB. Priority date: 08/11/2010. Publication date: 29/08/2013.
3. Mosińska P, Fichna J, Storr M. (2015)
Inhibition of ileal bile acid transporter: An emerging therapeutic strategy for chronic idiopathic constipation.
World J. Gastroenterol., 21 (24): 7436-42. [PMID:26139989]
4. Nakajima A, Seki M, Taniguchi S, Ohta A, Gillberg PG, Mattsson JP, Camilleri M. (2018)
Safety and efficacy of elobixibat for chronic constipation: results from a randomised, double-blind, placebo-controlled, phase 3 trial and an open-label, single-arm, phase 3 trial.
Lancet Gastroenterol Hepatol, 3 (8): 537-547. [PMID:29805116]
5. Nakajima A, Taniguchi S, Kurosu S, Gillberg PG, Mattsson JP, Camilleri M. (2019)
Efficacy, long-term safety, and impact on quality of life of elobixibat in more severe constipation: Post hoc analyses of two phase 3 trials in Japan.
Neurogastroenterol. Motil., 31 (5): e13571. [PMID:30793431]
6. Wong BS, Camilleri M. (2013)
Elobixibat for the treatment of constipation.
Expert Opin Investig Drugs, 22 (2): 277-84. [PMID:23215781]